Focused on Delivering Affordable Biomedicines
We are building our capabilities to handle a range of biologic medicines, including insulin, monoclonal antibodies (mABs), and anti-obesity drugs.
Cellxis: Pioneering Affordable Biopharmaceuticals in Asia
Founded in 2024, Cellxis was established with a vision to supply biopharmaceutical medicines at affordable prices to patients in Asia in partnership with leading biologics companies.
The company is building capabilities to handle a range of biologic medicines, including insulin, monoclonal antibodies (mABs), and weight-loss drugs. It’s mission is to increase patients’ access to these much needed treatments for diabetes and cancer and cardiovascular diseases.
The company is building capabilities to handle a range of biologic medicines, including insulin, monoclonal antibodies (mABs), and weight-loss drugs. It’s mission is to increase patients’ access to these much needed treatments for diabetes and cancer and cardiovascular diseases.
The company’s brand-new facility just outside of Bangkok, Thailand, is part of a multi-phase development of its capability. This fill-finish facility is optimized for high throughput with world-class equipment.
The capacity and capability building will continue to include reformulation facilities to offer medicines in vials, cartridges, and prefill pens.
State-of-the-Art Biopharmaceutical Facility in Bangkok, Thailand
Our brand-new facility just outside of Bangkok, Thailand, part of a multi-phase development of our capability, is a fill-finish facility optimized for high throughput with world-class equipment and will become operational in 2026.
Our capacity and capability building will continue to include reformulation facilities to offer medicines in vials, cartridges, and prefill pens.
